Careers  |  Sign In  |  Register  |   Twitter

Sanofi Teams Up with MannKind, Will Buy Rights to First Inhaled Insulin Product

Sanofi has signed on with MannKind Corp. to purchase rights to Afrezza, the world’s first and only inhaled insulin product, an article published by Bloomberg News reports. MannKind Corp. will be paid $150 million up front, and as much as $925 million total for Afrezza, which received its FDA approval seven weeks ago. Sanofi has also partnered with Medtronic Inc. this summer to market an insulin device, though the company says that Afrezza will serve to complement its existing relationship with Medtronic’s insulin product.

Read the article published by Bloomberg News.